- Home
- STNG vs IBRX Comparison
STNG vs IBRX Comparison
Compare STNG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STNG | IBRX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 8.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | STNG | IBRX |
|---|---|---|
| Price | $75.52 | $7.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $79.00 | $12.57 |
| AVG Volume (30 Days) | 1.3M | ★ 24.4M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $0.18 | $88.59 |
| Revenue Next Year | N/A | $131.15 |
| P/E Ratio | $10.06 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $31.62 | $1.83 |
| 52 Week High | $81.85 | $12.43 |
Technical Indicators
Market Signals| Indicator | STNG | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 45.27 |
| Support Level | $57.95 | $2.25 |
| Resistance Level | $81.85 | $8.28 |
| Average True Range (ATR) | 2.82 | 0.89 |
| MACD | 0.11 | -0.25 |
| Stochastic Oscillator | 89.74 | 28.17 |
Price Performance
Historical ComparisonAbout STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.